Graphite Bio, Inc. (NASDAQ:GRPH – Get Free Report) traded up 0.4% during trading on Friday . The company traded as high as $2.35 and last traded at $2.34. 63,669 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 179,417 shares. The stock had previously closed at $2.33.
Graphite Bio Trading Up 0.4 %
The stock has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.61. The firm has a market cap of $135.67 million, a P/E ratio of -1.02 and a beta of -0.05.
Graphite Bio (NASDAQ:GRPH – Get Free Report) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). As a group, equities analysts forecast that Graphite Bio, Inc. will post -1.67 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Graphite Bio
Graphite Bio Company Profile
Graphite Bio, Inc, a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
- Five stocks we like better than Graphite Bio
- Want to Profit on the Downtrend? Downtrends, Explained.
- Data giants MongoDB and Snowflake just got upgraded
- What is the Nikkei 225 index?
- Plug Power at tipping point; it’s make or break time for hydrogen
- 10 Best Airline Stocks to Buy
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Graphite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graphite Bio and related companies with MarketBeat.com's FREE daily email newsletter.